口腔外科術後のMRSA感染症に対するArbekacinの臨床効果

抄録

Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery.
ABK was administered by intravenous drip infusion at a dose of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously.
The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect, MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases.
In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.